

SUPERNUS PHARMACEUTICALS INC  
 Form 4  
 March 26, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIGHAM MICHAEL**

(Last) (First) (Middle)

C/O ABINGWORTH  
 MANAGEMENT INC, 890  
 WINTER STREET, SUITE 150

(Street)

WALTHAM, MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**SUPERNUS  
 PHARMACEUTICALS INC  
 [SUPN]**

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 03/20/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2013		P	5,000 A	\$ 5,172 (1) 5,000	I	By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
Common Stock	03/20/2013		P	5,000 A	\$ 5,195 (2) 5,000	I	By Cabot Forbes Bigham

Common Stock	03/20/2013		P	10,000	A	\$ 5.264 <u>(3)</u>	10,000	I	Trust U/A DTD 10/11/1996  By Michael F Bigham CRUT U/A DTD 11/23/1994
Common Stock	03/22/2013		P	15,000	A	\$ 5.653 <u>(4)</u>	25,000	I	By Michael F Bigham CRUT U/A DTD 11/23/1994

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Priority of Derivative Security (Instr. 3)
Director Stock Option (Right to Buy)	\$ 7.9					Date Exercisable: 02/05/2014 Expiration Date: 02/05/2023	Common Stock	Amount or Number of Shares: 8,722

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BIGHAM MICHAEL  
C/O ABINGWORTH MANAGEMENT INC X  
890 WINTER STREET, SUITE 150  
WALTHAM, MA 02451

## Signatures

/s/ Gregory S. Patrick, as  
attorney-in-fact 03/26/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.11 to \$5.20, inclusive. The Reporting Person undertakes to provide to any security holder of Supernus Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4).
- (2) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.17 to 5.20, inclusive.
- (3) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.18 to 5.49, inclusive.
- (4) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.53 to 5.68, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.